

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/080,917 02/22/2002		Patrick Cadet	09598-006001	09598-006001 7797	
26191	7590	06/14/2004		EXAMINER	
FISH & RI 3300 DAIN			LANDSMAN, ROBERT S		
60 SOUTH			ART UNIT	PAPER NUMBER	
MINNEAPOLIS, MN 55402				1647	

DATE MAILED: 06/14/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/080,917	CADET ET AL.				
Office Action Summary	Examiner	Art Unit				
	Robert Landsman	1647				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be tin within the statutory minimum of thirty (30) day ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed is will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
	action is non-final.					
3) Since this application is in condition for allowant	ce except for formal matters, pro	secution as to the merits is				
closed in accordance with the practice under Ex	k parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-32</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdraw	n from consideration					
5) Claim(s) is/are allowed.	in nom consideration.					
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-32</u> are subject to restriction and/or el	ection requirement.					
pplication Papers						
· · _						
9) The specification is objected to by the Examiner.10) The drawing(s) filed on is/are: a) accept		-vamain a				
Applicant may not request that any objection to the di						
Replacement drawing sheet(s) including the correction		` '				
11) The oath or declaration is objected to by the Exa						
		7.64.617.617.617.7.7.2.				
riority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-	-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents						
2. Certified copies of the priority documents3. Copies of the certified copies of the priorit						
 Copies of the certified copies of the priorit application from the International Bureau 		d in this National Stage				
* See the attached detailed Office action for a list of		4				
200 and altached dotailed Office action for a list of	the certified copies not received	J.				
tachment(s)						
Notice of References Cited (PTO-892)	4) Interview Summary (
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date Notice of Informal Patent Application (PTO-152)						
Paper No(s)/Mail Date	6) Other:					
Calent and Trademark Office						

DETAILED ACTION

1. Election/Restriction

- A. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-14, drawn to isolated nucleic acid molecule and host cell, classified in class 435, subclass 69.1.
 - II. Claims 15-19, drawn to an isolated polypeptide, classified in class 530, subclass 350.
 - III. Claims 20-27, drawn to a method of screening for agonists, classified in class 435, subclass 7.2.
 - IV. Claims 28-31, drawn to a method of screening for antagonists, classified in class 435, subclass 7.2.
 - V. Claims 32, drawn to isolated nucleic acid molecule of SEQ ID NO:22, classified in class 435, subclass 69.1.
- B. The inventions are distinct, each from each other because of the following reasons:

Inventions I, II and V are independent and distinct, each from each other, because they are products which possess characteristic differences in structure and function and each has an independent utility that is distinct for each invention which cannot be exchanged. The nucleic acid of Group II can be used to make a hybridization probe, or can be used in gene therapy as well as to produce the protein of interest.

Inventions I, V are unrelated to II, IV. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed as capable of use together.

Inventions II and III, IV are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product, or (2) the product as claimed can be used in a materially different process of using that product MPEP § 806.05(h).

Inventions III and IV are independent and distinct, each from the other, because the methods are practiced with materially different process steps for materially different purposes and each method requires a non-coextensive search because of different starting materials, process steps and goals.

Art Unit: 1647

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

Furthermore, in order to be fully responsive, if Applicants elect Groups I-IV, Applicants must also elect one protein (SEQ ID NO:2, 5, 7, 9 or 11) and, depending on the elected Group, the nucleic acid molecules corresponding to that protein (SEQ ID NO:1, 3, 4, 6, 8 or 10).

C. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR § 1.48(b) and by the fee required under 37 CFR § 1.17 (h).

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (703) 306-3407. The examiner can normally be reached on Monday - Friday from 8:00 AM to 5:00 PM (Eastern time) and alternate Fridays from 8:00 AM to 5:00 PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242. Fax draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Robert Landsman, Ph.D. Patent Examiner Group 1600 June 11, 2004

PATENT EXAMINEN